Skip to content
ABOUT
AUTHOR GUIDELINES
AUTHORS/EDITORS
SUBSCRIPTIONS
CONTACT US
MY ACCOUNT
Facebook
X
LinkedIn
Instagram
Search
×
HOME
PSYCH. BULLETIN
LATEST ISSUE
BLACK BOOK OF DOSING & MONITORING
RATING SCALES
LICENSING INFORMATION
RESOURCES
PSYCHOTROPICS A-Z
PSYCHOPHARMACOLOGY 101
NEWS
A Pilot Evaluating Clinical Pharmacy Services in an Ambulatory Psychiatry Setting
1
x
$
30.00
New Developments in the Neurobiological Basis of Anxiety Disorders
1
x
$
30.00
View Cart
Checkout
Home
David V. Sheehan: An Open-Label Study of Tiagabine in Panic Disorder
“New Developments in the Neurobiological Basis of Anxiety Disorders” has been added to your cart.
View cart
David V. Sheehan: An Open-Label Study of Tiagabine in Panic Disorder
$
30.00
David V. Sheehan: An Open-Label Study of Tiagabine in Panic Disorder quantity
Add to cart
Want a discount? Become a member by purchasing
Psychopharmacology Bulletin Subscription - Individual
!
SKU:
pb-40-3-sheehan
Categories:
Psychopharmacology Bulletin
,
VOL 40 No. 3 Articles
Tags:
aminobutyric-acid-gaba
,
anxiety
,
b-ashok-raj
,
david-v-sheehan
,
juris-janavs
,
kathy-harnett-sheehan
,
mba
,
md
,
panic-disorder
,
phd
,
selective-gaba-reuptake-inhibitor
,
tiagabine
Description
Description
David V. Sheehan, MD
Link
NEGATIVE AND FAILED CLINICAL TRIAL REPORTS
An Open-Label Study of Tiagabine in
Panic Disorder
David V. Sheehan, MD, MBA, Kathy Harnett Sheehan, PhD, B. Ashok Raj, MD, and Juris Janavs, MD
Related products
Theodore J. Anfinson, MD: Akathisia, Panic, Agoraphobia, and Major Depression Following Brief Exposure to Metoclopramide
$
30.00
Add to cart
Details
Michael S. Clark, MD, PhD: The 5-HT1B Receptor: Behavioral Implications
$
30.00
Add to cart
Details
Neurobiology and Mechanisms of Antidepressant Treatment Response in Anxiety
$
30.00
Add to cart
Details
Eileen P. Ahearn, MD, PhD: Fear, Anxiety, and the Neuroimaging of PTSD
$
30.00
Add to cart
Details
Page load link
Go to Top
